Epidemiology of mucopolysaccharidoses.
Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S.
Mol Genet Metab. 2017 Jul;121(3):227-240. doi: 10.1016/j.ymgme.2017.05.016. Epub 2017 May 26.
Phagocytic defects--monocytes/macrophages.
Douglas SD, Musson RA.
Clin Immunol Immunopathol. 1986 Jul;40(1):62-8. doi: 10.1016/0090-1229(86)90069-3.
Gene therapy for Mucopolysaccharidoses.
Sawamoto K, Chen HH, Alméciga-Díaz CJ, Mason RW, Tomatsu S.
Mol Genet Metab. 2018 Feb;123(2):59-68. doi: 10.1016/j.ymgme.2017.12.434. Epub 2017 Dec 26.
Mucopolysaccharidoses type I gene therapy.
Hurt SC, Dickson PI, Curiel DT.
J Inherit Metab Dis. 2021 Sep;44(5):1088-1098. doi: 10.1002/jimd.12414. Epub 2021 Jul 9.
Advances in glycosaminoglycan detection.
Khan SA, Mason RW, Kobayashi H, Yamaguchi S, Tomatsu S.
Mol Genet Metab. 2020 Jun;130(2):101-109. doi: 10.1016/j.ymgme.2020.03.004. Epub 2020 Mar 27.
Current and new therapies for mucopolysaccharidoses.
Penon-Portmann M, Blair DR, Harmatz P.
Pediatr Neonatol. 2023 Feb;64 Suppl 1:S10-S17. doi: 10.1016/j.pedneo.2022.10.001. Epub 2022 Oct 26.
Growth impairment in mucopolysaccharidoses.
Melbouci M, Mason RW, Suzuki Y, Fukao T, Orii T, Tomatsu S.
Mol Genet Metab. 2018 May;124(1):1-10. doi: 10.1016/j.ymgme.2018.03.004. Epub 2018 Mar 16.
Lysosomal sulfatases: a growing family.
Lübke T, Damme M.
Biochem J. 2020 Oct 30;477(20):3963-3983. doi: 10.1042/BCJ20200586.
Glycan-based biomarkers for mucopolysaccharidoses.
Lawrence R, Brown JR, Lorey F, Dickson PI, Crawford BE, Esko JD.
Mol Genet Metab. 2014 Feb;111(2):73-83. doi: 10.1016/j.ymgme.2013.07.016. Epub 2013 Jul 29.
Therapies for the bone in mucopolysaccharidoses.
Tomatsu S, Alméciga-Díaz CJ, Montaño AM, Yabe H, Tanaka A, Dung VC, Giugliani R, Kubaski F, Mason RW, Yasuda E, Sawamoto K, Mackenzie W, Suzuki Y, Orii KE, Barrera LA, Sly WS, Orii T.
Mol Genet Metab. 2015 Feb;114(2):94-109. doi: 10.1016/j.ymgme.2014.12.001. Epub 2014 Dec 9.
